Natural History of Amyloid Deposition in Adults With Down Syndrome
|ClinicalTrials.gov Identifier: NCT01303133|
Recruitment Status : Active, not recruiting
First Posted : February 24, 2011
Last Update Posted : August 1, 2017
|Condition or disease|
Specific Aim 1: To assess and compare amyloid deposition (with PiB PET) in non-demented/functionally stable adults with DS across three age cohorts (30-39, 40-49, and >50 years of age).
Primary Hypothesis 1: At initial assessment, there will be a significantly higher prevalence of amyloid-positive (PiB+) subjects in each succeeding age cohort.
In addition, we will test the following secondary hypothesis:
Secondary Aim 1: To compare the presence or absence of the apolipoprotein-E4 allele to the retention of PiB in various brain areas of the DS subjects.
Secondary Hypothesis 1: At baseline, subjects who carry at least one Apolipoprotein-E4 (ApoE4) allele will show a higher prevalence of being PiB+.
|Study Type :||Observational|
|Actual Enrollment :||81 participants|
|Official Title:||Natural History of Amyloid Deposition in Adults With Down Syndrome|
|Study Start Date :||August 2009|
|Estimated Primary Completion Date :||March 31, 2018|
|Estimated Study Completion Date :||March 31, 2018|
Adults with Down Syndrome ages 30+
We will be recruiting healthy adults with Down syndrome ages 30 and over. Participants cannot have a diagnosis of dementia.
- Amyloid deposition [ Time Frame: every 36 months for 9 years ]Obtained via PiB PET scan
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01303133
|United States, Pennsylvania|
|University of Pittsburgh and University of Pittsburgh Medical Center|
|Pittsburgh, Pennsylvania, United States, 15203|
|United States, Wisconsin|
|Waisman Center at the University of Wisconsin - Madison|
|Madison, Wisconsin, United States, 53705|
|Principal Investigator:||Benjamin Handen, PhD||University of Pittsburgh|